Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Clorazepic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | ALB | P02768 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.64 |
| ▸ | CCKBR | P32239 | 4/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clorazepic Acid SCHEMBL27617141 | 1.00 | LMNA (0.72) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL1302660 | 1.00 | LMNA (0.72) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL4287456 | 1.00 | LMNA (0.72) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL21462311 | 0.99 | LMNA (0.70) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL34618 | 0.99 | LMNA (0.73) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL1649064 | 0.99 | LMNA (0.73) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL29484725 | 0.99 | LMNA (0.73) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL34617 | 0.99 | LMNA (0.73) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL9694061 | 0.98 | LMNA (0.72) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL1225017 | 0.96 | LMNA (0.67) | LMNAMEN1ALBKMT2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 752 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| US-20240000810-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF TOURETTE SYNDROME AND TIC DISORDERS | Orcosa Inc. (US) | 2024-01-04 | — | — | US | claimed |
| US-20210353751-A1 | COMBINATION THERAPIES FOR TREATMENT OF INFLAMMATORY DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-18 | — | — | US | claimed |
| US-20210205248-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-08 | — | — | US | claimed |
| EP-3770159-A1 | BENZOQUINOLONE INHIBITOR OF VMAT2 | Auspex Pharmaceuticals, Inc. (US) | 2021-01-27 | — | — | EP | claimed |
| EP-3753410-A2 | COMBINATIONS COMPRISING GABA AGONISTS IN TREATMENT OF HYPERGLYCEMIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-23 | — | — | EP | claimed |
| US-20200345722-A1 | ABUSE-DETERRENT DRUG FORMULATIONS | COLLEGIUM PHARMACEUTICAL INC (US) | 2020-11-05 | — | — | US | claimed |
| US-20200345723-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL INC (US) | 2020-11-05 | — | — | US | claimed |
| WO-2020081885-A1 | COMBINATION THERAPIES FOR TREATMENT OF INFLAMMATORY DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-04-23 | — | — | WO | claimed |
| US-20200093820-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2020-03-26 | — | — | US | claimed |
| EP-1594467-A4 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL INC (US) | 2008-10-22 | — | — | EP | claimed |
| US-7399488-B2 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2008-07-15 | — | — | US | claimed |
| EP-1765292-A1 | ABUSE-DETERRENT DRUG FORMULATIONS | Collegium Pharmaceutical, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| US-20060014697-A1 | Pharmaceutical compositions for prevention of overdose or abuse | SHIRE LLC | 2006-01-19 | — | — | US | claimed |
| WO-2005123039-A1 | ABUSE-DETERRENT DRUG FORMULATIONS | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2005-12-29 | — | — | WO | claimed |
| US-20050281748-A1 | Abuse-deterrent drug formulations | COLLEGIUM PHARMACEUTICAL, INC. | 2005-12-22 | — | — | US | claimed |
| EP-1594467-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | Collegium Pharmaceutical, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040058946-A1 | Abuse-resistant prodrugs of oxycodone and other pharmaceuticals | COLLEGIUM PHARMACEUTICAL, INC. | 2004-03-25 | — | — | US | claimed |
| US-20040052731-A1 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs | COLLEGIUM PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | claimed |
| WO-2004004693-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS | COLLGEGIUM PHARMACEUTICAL (US) | 2004-01-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205248-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | GABRA4, GPR119, GABRG3 | LMNA 3158/4885MEN1 554/4885ALB 607/4885 |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | ACAT2, CPT1A, SLC18A2 | LMNA 1919/4885MEN1 3836/4885ALB 4878/4885 |
| US-20040058946-A1 | Abuse-resistant prodrugs of oxycodone and other pharmaceuticals | OPRK1, OPRM1, OPRL1 | LMNA 4776/4885MEN1 4873/4885ALB 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.